---All---
  • ---All---
  • Accession
  • Catalog #

PI3KC3 Antibody (S851) Blocking PeptideSynthetic peptide

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
BP1851j 0.1 mg 400 ul In Stock $ 45.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

PI3KC3 Antibody (S851) Blocking Peptide - Product info

Primary AccessionQ8NEB9
Clone Names70226222
Calculated MW101549 Da

PI3KC3 Antibody (S851) Blocking Peptide - Additional info

Gene ID 5289
Target/Specificity
The synthetic peptide sequence used to generate the antibody AP1851j was selected from the S851 region of human PI3KC3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Format
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

PI3KC3 Antibody (S851) Blocking Peptide - Protein Information

Name PIK3C3
Synonyms VPS34
Function
Catalytic subunit of the PI3K complex that mediates formation of phosphatidylinositol 3-phosphate which plays a key role in initiation and maturation of autophagosomes. Involved in the transport of lysosomal enzyme precursors to lysosomes Required for the abcission step in cytokinesis. Required for transport from early to late endosomes
Cellular Location
Midbody. Late endosome.
Tissue Location
Ubiquitously expressed, with a highest expression in skeletal muscle

PI3KC3 Antibody (S851) Blocking Peptide - Related products

AP1851a: PI3KC3 Antibody (N-term G24)

AP1851b: PI3KC3 Antibody (C-term E785)

AP1851c: PI3KC3 Antibody (Center K269)

AP1851d: PI3KC3 Antibody (Center E501)

AP1851e: PI3KC3 Antibody (S34)

AP1851g: PI3KC3 Antibody (S164)

AP1851h: PI3KC3 Antibody (S425)

AP1851j: PI3KC3 Antibody (S851)

AP3368a: Phospho-PI3KC3-S282 Antibody

AP3369a: Phospho-PI3KC3-S676 Antibody

AP3399a: Phospho-PI3KC3-S164 Antibody

AP8014a: PI3KC3 Antibody (N-term)

RI13993: PIK3C3 predesign siRNA

BP1851a: Kinase PI3KC3 Antibody (N-term) Blocking Peptide

BP1851b: Kinase PI3KC3 Antibody (C-term) Blocking Peptide

BP1851c: Kinase PI3KC3 Antibody (Center K269) Blocking Peptide

BP1851e: PI3KC3 Antibody (S34) Blocking Peptide

BP1851g: PI3KC3 Antibody (S164) Blocking Peptide

BP1851h: PI3KC3 Antibody (S425) Blocking Peptide

BP1851j: PI3KC3 Antibody (S851) Blocking Peptide

BP3368a: Phospho-PI3KC3-S282 Antibody Blocking Peptide

BP3369a: Phospho-PI3KC3-S676 Antibody Blocking Peptide

BP3399a: Phospho-PI3KC3-S164 Antibody Blocking Peptide

BP8014a: PI3KC3 Antibody (N-term) Blocking Peptide

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

PI3KC3 is a catalytic subunit of the PI3K complex involved in the transport of lysosomal enzyme precursors to lysosomes. This enzyme acts catalytically to convert 1-phosphatidyl-1D-myo-inositol to 1-phosphatidyl-1D-myo-inositol 3-phosphate.Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). The regulation of the Beclin 1-PI3KC3 complex lipid kinase activity is a critical element in the autophagy signaling pathway.

REFERENCES

Vergne, I., et al., J. Exp. Med. 198(4):653-659 (2003).Volinia, S., et al., EMBO J. 14(14):3339-3348 (1995).